Certara, Inc. CERT Reportable Segment — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Certara, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Certara, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Certara, Inc.'s reportable segment — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Certara, Inc.'s reportable segment — revenue?
- Certara, Inc. (CERT) reported reportable segment — revenue of $106.92M in Q1 2026.
- How has Certara, Inc.'s reportable segment — revenue changed year-over-year?
- Certara, Inc.'s reportable segment — revenue increased by 0.9% year-over-year, from $106M to $106.92M.
- What is the long-term trend for Certara, Inc.'s reportable segment — revenue?
- Over 3 years (2022 to 2025), Certara, Inc.'s reportable segment — revenue has grown at a 7.7% compound annual growth rate (CAGR), from $335.64M to $418.84M.
- What does reportable segment — revenue mean?
- This metric represents the total gross income generated by the company's primary business segment through the sale of biosimulation software, regulatory science services, and related technology solutions. It serves as the primary indicator of the segment's market demand and top-line growth performance. Monitoring this figure helps investors assess the segment's ability to scale its core offerings within the drug discovery and development lifecycle.